TY - JOUR AU - Arbour, K. C. AU - Riely, G. J. PY - 2019 DA - 2019// TI - Systemic therapy for locally advanced and metastatic non-small cell lung Cancer: a review JO - JAMA VL - 322 UR - https://doi.org/10.1001/jama.2019.11058 DO - 10.1001/jama.2019.11058 ID - Arbour2019 ER - TY - JOUR AU - Tartarone, A. AU - Lerose, R. PY - 2015 DA - 2015// TI - Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance JO - Ther Adv Respir Dis VL - 9 UR - https://doi.org/10.1177/1753465815587820 DO - 10.1177/1753465815587820 ID - Tartarone2015 ER - TY - JOUR AU - Gelatti, A. C. Z. AU - Drilon, A. AU - Santini, F. C. PY - 2019 DA - 2019// TI - Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) JO - Lung Cancer VL - 137 UR - https://doi.org/10.1016/j.lungcan.2019.09.017 DO - 10.1016/j.lungcan.2019.09.017 ID - Gelatti2019 ER - TY - JOUR AU - Kobayashi, S. AU - Boggon, T. J. AU - Dayaram, T. AU - Janne, P. A. AU - Kocher, O. AU - Meyerson, M. PY - 2005 DA - 2005// TI - EGFR mutation and resistance of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa044238 DO - 10.1056/NEJMoa044238 ID - Kobayashi2005 ER - TY - JOUR AU - Engelman, J. A. AU - Zejnullahu, K. AU - Mitsudomi, T. AU - Song, Y. AU - Hyland, C. AU - Park, J. O. PY - 2007 DA - 2007// TI - MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling JO - Science VL - 316 UR - https://doi.org/10.1126/science.1141478 DO - 10.1126/science.1141478 ID - Engelman2007 ER - TY - JOUR AU - Leonetti, A. AU - Sharma, S. AU - Minari, R. AU - Perego, P. AU - Giovannetti, E. AU - Tiseo, M. PY - 2019 DA - 2019// TI - Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer JO - Br J Cancer VL - 121 UR - https://doi.org/10.1038/s41416-019-0573-8 DO - 10.1038/s41416-019-0573-8 ID - Leonetti2019 ER - TY - JOUR AU - Mehlman, C. AU - Cadranel, J. AU - Rousseau-Bussac, G. AU - Lacave, R. AU - Pujals, A. AU - Girard, N. PY - 2019 DA - 2019// TI - Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study JO - Lung Cancer VL - 137 UR - https://doi.org/10.1016/j.lungcan.2019.09.019 DO - 10.1016/j.lungcan.2019.09.019 ID - Mehlman2019 ER - TY - JOUR AU - Lai, G. G. Y. AU - Lim, T. H. AU - Lim, J. AU - Liew, P. J. R. AU - Kwang, X. L. AU - Nahar, R. PY - 2019 DA - 2019// TI - Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung Cancer JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.00177 DO - 10.1200/JCO.18.00177 ID - Lai2019 ER - TY - JOUR AU - Senichkin, V. V. AU - Streletskaia, A. Y. AU - Zhivotovsky, B. AU - Kopeina, G. S. PY - 2019 DA - 2019// TI - Molecular comprehension of Mcl-1: from gene structure to Cancer therapy JO - Trends Cell Biol VL - 29 UR - https://doi.org/10.1016/j.tcb.2019.03.004 DO - 10.1016/j.tcb.2019.03.004 ID - Senichkin2019 ER - TY - JOUR AU - Xiang, W. AU - Yang, C. Y. AU - Bai, L. PY - 2018 DA - 2018// TI - MCL-1 inhibition in cancer treatment JO - Onco Targets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S146228 DO - 10.2147/OTT.S146228 ID - Xiang2018 ER - TY - JOUR AU - Yamaguchi, R. AU - Lartigue, L. AU - Perkins, G. PY - 2019 DA - 2019// TI - Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy JO - Pharmacol Ther VL - 195 UR - https://doi.org/10.1016/j.pharmthera.2018.10.009 DO - 10.1016/j.pharmthera.2018.10.009 ID - Yamaguchi2019 ER - TY - JOUR AU - Booy, E. P. AU - Henson, E. S. AU - Gibson, S. B. PY - 2011 DA - 2011// TI - Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer JO - Oncogene VL - 30 UR - https://doi.org/10.1038/onc.2010.616 DO - 10.1038/onc.2010.616 ID - Booy2011 ER - TY - JOUR AU - Song, K. A. AU - Hosono, Y. AU - Turner, C. AU - Jacob, S. AU - Lochmann, T. L. AU - Murakami, Y. PY - 2018 DA - 2018// TI - Increased synthesis of MCL-1 protein underlies initial survival of EGFR-mutant lung Cancer to EGFR inhibitors and provides a novel drug target JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-18-0304 DO - 10.1158/1078-0432.CCR-18-0304 ID - Song2018 ER - TY - JOUR AU - Tay, K. C. AU - Tan, L. T. AU - Chan, C. K. AU - Hong, S. L. AU - Chan, K. G. AU - Yap, W. H. PY - 2019 DA - 2019// TI - Formononetin: a review of its anticancer potentials and mechanisms JO - Front Pharmacol VL - 10 UR - https://doi.org/10.3389/fphar.2019.00820 DO - 10.3389/fphar.2019.00820 ID - Tay2019 ER - TY - JOUR AU - Ong, S. K. L. AU - Shanmugam, M. K. AU - Fan, L. AU - Fraser, S. E. AU - Arfuso, F. AU - Ahn, K. S. PY - 2019 DA - 2019// TI - Focus on Formononetin: Anticancer Potential and Molecular Targets JO - Cancers (Basel) VL - 11 UR - https://doi.org/10.3390/cancers11050611 DO - 10.3390/cancers11050611 ID - Ong2019 ER - TY - JOUR AU - Yang, C. AU - Xie, Q. AU - Zeng, X. AU - Tao, N. AU - Xu, Y. AU - Chen, Y. PY - 2019 DA - 2019// TI - Novel hybrids of podophyllotoxin and formononetin inhibit the growth, migration and invasion of lung cancer cells JO - Bioorg Chem VL - 85 UR - https://doi.org/10.1016/j.bioorg.2019.02.019 DO - 10.1016/j.bioorg.2019.02.019 ID - Yang2019 ER - TY - JOUR AU - Zhang, L. AU - Gong, Y. AU - Wang, S. AU - Gao, F. PY - 2019 DA - 2019// TI - Anti-colorectal Cancer mechanisms of Formononetin identified by network pharmacological approach JO - Med Sci Monit VL - 25 UR - https://doi.org/10.12659/MSM.919935 DO - 10.12659/MSM.919935 ID - Zhang2019 ER - TY - JOUR AU - Xin, M. AU - Wang, Y. AU - Ren, Q. AU - Guo, Y. PY - 2019 DA - 2019// TI - Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro JO - Biomed Pharmacother VL - 109 UR - https://doi.org/10.1016/j.biopha.2018.09.033 DO - 10.1016/j.biopha.2018.09.033 ID - Xin2019 ER - TY - JOUR AU - Yao, J. N. AU - Zhang, X. X. AU - Zhang, Y. Z. AU - Li, J. H. AU - Zhao, D. Y. AU - Gao, B. PY - 2019 DA - 2019// TI - Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells JO - Investig New Drugs VL - 37 UR - https://doi.org/10.1007/s10637-019-00767-7 DO - 10.1007/s10637-019-00767-7 ID - Yao2019 ER - TY - JOUR AU - Zhou, L. AU - Yu, X. AU - Li, M. AU - Gong, G. AU - Liu, W. AU - Li, T. PY - 2019 DA - 2019// TI - Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth JO - EBioMedicine VL - 51 UR - https://doi.org/10.1016/j.ebiom.2019.11.031 DO - 10.1016/j.ebiom.2019.11.031 ID - Zhou2019 ER - TY - JOUR AU - Li, W. AU - Yu, X. AU - Xia, Z. AU - Yu, X. AU - Xie, L. AU - Ma, X. PY - 2018 DA - 2018// TI - Repression of Noxa by Bmi1 contributes to deguelin-induced apoptosis in non-small cell lung cancer cells JO - J Cell Mol Med VL - 22 UR - https://doi.org/10.1111/jcmm.13908 DO - 10.1111/jcmm.13908 ID - Li2018 ER - TY - JOUR AU - Zhang, Y. AU - Yao, K. AU - Shi, C. AU - Jiang, Y. AU - Liu, K. AU - Zhao, S. PY - 2015 DA - 2015// TI - 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells JO - Oncotarget VL - 6 ID - Zhang2015 ER - TY - JOUR AU - Sheng, Y. AU - Li, W. AU - Zhu, F. AU - Liu, K. AU - Chen, H. AU - Yao, K. PY - 2014 DA - 2014// TI - 3,6,2′,4′,5′-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M114.593475 DO - 10.1074/jbc.M114.593475 ID - Sheng2014 ER - TY - JOUR AU - Sali, A. AU - Blundell, T. L. PY - 1993 DA - 1993// TI - Comparative protein modelling by satisfaction of spatial restraints JO - J Mol Biol VL - 234 UR - https://doi.org/10.1006/jmbi.1993.1626 DO - 10.1006/jmbi.1993.1626 ID - Sali1993 ER - TY - JOUR AU - Berman, H. M. AU - Westbrook, J. AU - Feng, Z. AU - Gilliland, G. AU - Bhat, T. N. AU - Weissig, H. PY - 2000 DA - 2000// TI - The Protein Data Bank JO - Nucleic Acids Res VL - 28 UR - https://doi.org/10.1093/nar/28.1.235 DO - 10.1093/nar/28.1.235 ID - Berman2000 ER - TY - JOUR AU - Yu, X. AU - Wang, R. AU - Zhang, Y. AU - Zhou, L. AU - Wang, W. AU - Liu, H. PY - 2019 DA - 2019// TI - Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin JO - Oncogene VL - 38 UR - https://doi.org/10.1038/s41388-019-0955-7 DO - 10.1038/s41388-019-0955-7 ID - Yu2019 ER - TY - JOUR AU - Liu, H. AU - Li, W. AU - Yu, X. AU - Gao, F. AU - Duan, Z. AU - Ma, X. PY - 2016 DA - 2016// TI - EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis JO - Oncotarget VL - 7 ID - Liu2016 ER - TY - JOUR AU - Cross, D. A. AU - Alessi, D. R. AU - Cohen, P. AU - Andjelkovich, M. AU - Hemmings, B. A. PY - 1995 DA - 1995// TI - Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B JO - Nature VL - 378 UR - https://doi.org/10.1038/378785a0 DO - 10.1038/378785a0 ID - Cross1995 ER - TY - JOUR AU - Skoulidis, F. AU - Heymach, J. V. PY - 2019 DA - 2019// TI - Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy JO - Nat Rev Cancer VL - 19 UR - https://doi.org/10.1038/s41568-019-0179-8 DO - 10.1038/s41568-019-0179-8 ID - Skoulidis2019 ER - TY - JOUR AU - Santoni-Rugiu, E. AU - Melchior, L. C. AU - Urbanska, E. M. AU - Jakobsen, J. N. AU - Stricker, K. AU - Grauslund, M. PY - 2019 DA - 2019// TI - Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance JO - Cancers (Basel) VL - 11 UR - https://doi.org/10.3390/cancers11070923 DO - 10.3390/cancers11070923 ID - Santoni-Rugiu2019 ER - TY - JOUR AU - Akgul, C. PY - 2009 DA - 2009// TI - Mcl-1 is a potential therapeutic target in multiple types of cancer JO - Cell Mol Life Sci VL - 66 UR - https://doi.org/10.1007/s00018-008-8637-6 DO - 10.1007/s00018-008-8637-6 ID - Akgul2009 ER - TY - JOUR AU - Senichkin, V. V. AU - Streletskaia, A. Y. AU - Gorbunova, A. S. AU - Zhivotovsky, B. AU - Kopeina, G. S. PY - 2020 DA - 2020// TI - Saga of Mcl-1: regulation from transcription to degradation JO - Cell Death Differ VL - 1 ID - Senichkin2020 ER - TY - JOUR AU - Whitsett, T. G. AU - Mathews, I. T. AU - Cardone, M. H. AU - Lena, R. J. AU - Pierceall, W. E. AU - Bittner, M. PY - 2014 DA - 2014// TI - Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response JO - Mol Cancer Res VL - 12 UR - https://doi.org/10.1158/1541-7786.MCR-13-0458 DO - 10.1158/1541-7786.MCR-13-0458 ID - Whitsett2014 ER - TY - JOUR AU - Ding, Q. AU - He, X. AU - Hsu, J. M. AU - Xia, W. AU - Chen, C. T. AU - Li, L. Y. PY - 2007 DA - 2007// TI - Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization JO - Mol Cell Biol VL - 27 UR - https://doi.org/10.1128/MCB.00620-06 DO - 10.1128/MCB.00620-06 ID - Ding2007 ER - TY - JOUR AU - Tong, J. AU - Wang, P. AU - Tan, S. AU - Chen, D. AU - Nikolovska-Coleska, Z. AU - Zou, F. PY - 2017 DA - 2017// TI - Mcl-1 degradation is required for targeted therapeutics to eradicate Colon Cancer cells JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-3242 DO - 10.1158/0008-5472.CAN-16-3242 ID - Tong2017 ER - TY - JOUR AU - Arai, S. AU - Jonas, O. AU - Whitman, M. A. AU - Corey, E. AU - Balk, S. P. AU - Chen, S. PY - 2018 DA - 2018// TI - Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL/BCL2 inhibitors drive prostate Cancer apoptosis JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-18-0549 DO - 10.1158/1078-0432.CCR-18-0549 ID - Arai2018 ER - TY - JOUR AU - Nalluri, S. AU - Peirce, S. K. AU - Tanos, R. AU - Abdella, H. A. AU - Karmali, D. AU - Hogarty, M. D. PY - 2015 DA - 2015// TI - EGFR signaling defines Mcl (−)1 survival dependency in neuroblastoma JO - Cancer Biol Ther VL - 16 UR - https://doi.org/10.1080/15384047.2014.1002333 DO - 10.1080/15384047.2014.1002333 ID - Nalluri2015 ER - TY - JOUR AU - Cao, F. AU - Gong, Y. B. AU - Kang, X. H. AU - Lu, Z. H. AU - Wang, Y. AU - Zhao, K. L. PY - 2019 DA - 2019// TI - Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer JO - Toxicol Appl Pharmacol VL - 379 UR - https://doi.org/10.1016/j.taap.2019.114662 DO - 10.1016/j.taap.2019.114662 ID - Cao2019 ER - TY - JOUR AU - Shi, P. AU - Oh, Y. T. AU - Deng, L. AU - Zhang, G. AU - Qian, G. AU - Zhang, S. PY - 2017 DA - 2017// TI - Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK/ERK-dependent Bim and Mcl-1 degradation JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-1574 DO - 10.1158/1078-0432.CCR-17-1574 ID - Shi2017 ER - TY - JOUR AU - Fletcher, S. PY - 2019 DA - 2019// TI - MCL-1 inhibitors - where are we now (2019)? JO - Expert Opin Ther Pat VL - 29 UR - https://doi.org/10.1080/13543776.2019.1672661 DO - 10.1080/13543776.2019.1672661 ID - Fletcher2019 ER - TY - JOUR AU - Magiera, M. M. AU - Mora, S. AU - Mojsa, B. AU - Robbins, I. AU - Lassot, I. AU - Desagher, S. PY - 2013 DA - 2013// TI - Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons JO - Cell Death Differ VL - 20 UR - https://doi.org/10.1038/cdd.2012.124 DO - 10.1038/cdd.2012.124 ID - Magiera2013 ER - TY - JOUR AU - Zhong, Q. AU - Gao, W. AU - Du, F. AU - Wang, X. PY - 2005 DA - 2005// TI - Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis JO - Cell VL - 121 UR - https://doi.org/10.1016/j.cell.2005.06.009 DO - 10.1016/j.cell.2005.06.009 ID - Zhong2005 ER - TY - JOUR AU - Tong, J. AU - Tan, S. AU - Zou, F. AU - Yu, J. AU - Zhang, L. PY - 2017 DA - 2017// TI - FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2016.247 DO - 10.1038/onc.2016.247 ID - Tong2017 ER - TY - JOUR AU - Wu, X. AU - Luo, Q. AU - Zhao, P. AU - Chang, W. AU - Wang, Y. AU - Shu, T. PY - 2019 DA - 2019// TI - MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer JO - Proc Natl Acad Sci U S A VL - 116 UR - https://doi.org/10.1073/pnas.1814742116 DO - 10.1073/pnas.1814742116 ID - Wu2019 ER - TY - JOUR AU - Sun, H. AU - Kapuria, V. AU - Peterson, L. F. AU - Fang, D. AU - Bornmann, W. G. AU - Bartholomeusz, G. PY - 2011 DA - 2011// TI - Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-03-276477 DO - 10.1182/blood-2010-03-276477 ID - Sun2011 ER - TY - JOUR AU - Zhang, S. AU - Zhang, M. AU - Jing, Y. AU - Yin, X. AU - Ma, P. AU - Zhang, Z. PY - 2018 DA - 2018// TI - Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-017-02693-9 DO - 10.1038/s41467-017-02693-9 ID - Zhang2018 ER - TY - JOUR AU - Ye, M. AU - Zhang, Y. AU - Zhang, X. AU - Zhang, J. AU - Jing, P. AU - Cao, L. PY - 2017 DA - 2017// TI - Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung Cancer JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-3470 DO - 10.1158/0008-5472.CAN-16-3470 ID - Ye2017 ER -